Takeda: Kidney Diseases trials

The registry lists 17 Kidney Diseases studies with Takeda as lead sponsor. 2 are open to participants now and 9 have results posted.

Phase 1 2Phase 2 6Phase 3 5Phase 4 1No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Mezagitamab in Adults With Kidney Condition Called IgA NephropathyRecruitingNCT06963827Phase 3
• A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After TransplantationRecruitingNCT06243731
• A Study to Assess the Pharmacokinetics of Lanthanum Carbonate, Investigate and Compare the Efficacy, Safety and Tolerability of Lanthanum Carbonate With Calcium Carbonate in Hyperphosphataemic Children and Adolescents With Chronic Kidney Disease on DialysisCompletedNCT01696279Phase 2Results posted
• Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on DialysisCompletedNCT01478971Phase 3Results posted
• Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney DiseaseCompletedNCT01309828Phase 3Results posted
• Effect of Lanthanum Carbonate in Patients Previously Treated With Calcium-based Phosphate Binder TherapyCompletedNCT01130831Results posted
• Effects of Lanthanum Carbonate on FGF-23 in Subjects With Stage 3 CKDCompletedNCT01128179Phase 2Results posted
• Pharmacodynamic Study of Two Lanthanum Carbonate Formulations in Healthy AdultsCompletedNCT00880750Phase 1Results posted
• DELFT (Dynepo Evaluation of Long-Term Follow-Up Treatment)TerminatedNCT00664066Results posted
• Head to Head Study Against Sevelamer HydrochlorideCompletedNCT00441545Phase 3Results posted
• Efficacy and Safety of Peginesatide (AF37702) in the Treatment of Anemia in Participants With Chronic Kidney DiseaseCompletedNCT00314795Phase 2Results posted
• A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background TherapyCompletedNCT05174221Phase 1
• Efficacy and Safety of SM101 in the Treatment of IgA NephropathyWithdrawnNCT02605525Phase 2
• Efficacy and Safety of Weekly Subcutaneous MLN1202 in Improving Diabetic Nephropathy in Participants With MacroalbuminuriaWithdrawnNCT02410499Phase 2
• Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on HemodialysisWithdrawnNCT02015780Phase 3
• Conversion From Standard Phosphate Binder Therapy to Fosrenol® (Lanthanum Carbonate) in Chronic Kidney Disease Stage 5TerminatedNCT00452478Phase 4
• Efficacy and Safety of Lanthanum Carbonate in Reducing Serum Phosphorus Levels in Subjects With Stage 3 and 4 Chronic Kidney DiseaseCompletedNCT00234702Phase 2